WO2015167552A1 - Compositions topiques renfermant un extrait de bidens pour réduire les signes de l'âge - Google Patents

Compositions topiques renfermant un extrait de bidens pour réduire les signes de l'âge Download PDF

Info

Publication number
WO2015167552A1
WO2015167552A1 PCT/US2014/036223 US2014036223W WO2015167552A1 WO 2015167552 A1 WO2015167552 A1 WO 2015167552A1 US 2014036223 W US2014036223 W US 2014036223W WO 2015167552 A1 WO2015167552 A1 WO 2015167552A1
Authority
WO
WIPO (PCT)
Prior art keywords
bidens
skin
composition
extract
topical composition
Prior art date
Application number
PCT/US2014/036223
Other languages
English (en)
Inventor
Scott W. Wenzel
David J. Tyrrell
Alencia Vanay GRICE
Stephanie VandeVen TEAT
Jeffery Richard Seidling
Original Assignee
Kimberly-Clark Worldwide, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kimberly-Clark Worldwide, Inc. filed Critical Kimberly-Clark Worldwide, Inc.
Priority to PCT/US2014/036223 priority Critical patent/WO2015167552A1/fr
Publication of WO2015167552A1 publication Critical patent/WO2015167552A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations

Definitions

  • the present disclosure relates generally to compositions and methods to reduce the signs of skin aging of the face and body. More particularly, the present disclosure relates to compositions including an Undaria extract and/or Bidens extract and methods of topically applying the compositions for stimulating adipogenesis and lipogenesis to reduce signs of skin aging.
  • the skin of the face and neck areas are particularly prone to signs of aging. Signs of aging that affect the skin of the face and neck include, for example, wrinkles, fine lines, thinning skin, sagging skin, skin dryness and skin itchiness.
  • Vulvar skin and the labia are particular additional skin regions that change as a woman ages, especially as a result of the changes in hormone levels during and following menopause.
  • Vulvar skin and the labia can lose elasticity as a result of the degeneration of underlying fat and connective tissues, loss of collagen and thinning of the epithelial layer of the skin.
  • the vulvar skin can also become less moist.
  • the loss of elasticity and moisture of the mucosal vulvar skin can diminish the youthful look of the vulvar anatomy.
  • a woman can become ashamed and even depressed about the toll that aging takes on the appearance of her outer genitalia as a result of changes of the vulvar skin and labia.
  • compositions can be inappropriate for use on the delicate mucous membrane of the vulva and labia.
  • Incompatibility with mucosal skin necessitates alternative cosmetic creams and lotions specifically designed for application to reduce the effects of aging of the vulvar skin and labia.
  • the present disclosure is generally directed to compositions and methods to reduce the signs of skin aging.
  • the present disclosure is directed to a topical composition comprising a Bidens extract, a skin penetration enhancer, and a hydrophilic carrier.
  • the present disclosure is directed to a topical composition
  • a Bidens extract selected from the group consisting of Bidens pilosa extract, Bidens bipinnata extract, Bidens tripartita extract and combinations thereof, a skin penetration enhancer, and a hydrophilic carrier.
  • the present disclosure is directed to a topical composition
  • a topical composition comprising a Bidens pilosa extract, glycerin, a skin penetration enhancer, and a hydrophilic carrier.
  • FIGS. 2A-2F are photomicrographs of mouse 3T3-L1 cells showing Oil Red-0 staining after treatment of cells with various active ingredients, as discussed in Example 2.
  • FIGS. 3A-3F are photomicrographs of human adipose derived stem cells showing Oil Red-0 staining after treatment of cells with various active ingredients, as discussed in Example 2.
  • FIG. 5 is a photomicrograph of human ADSC stained red with Oil Red-O, demonstrating the production of fatty acids in response to treatment with Undaria extract, as discussed in Example 4.
  • FIGS. 6A-6F are photomicrographs of mouse 3T3-1L cells stained with Oil Red-0 following treatment with various extracts, as discussed in Example 5.
  • FIGS. 7A-7G are photomicrographs of mouse 3T3-1L cells stained with Oil Red-0 following treatment with additional active ingredients, as discussed in Example 6.
  • FIGS. 8A-8F are photomicrographs of mouse 3T3-1L cells stained red with Oil Red-0 following treatment with various Bidens extracts, as discussed in Example 7.
  • FIG. 9 is a graphical illustration showing percent cellular proliferation of human dermal fibroblasts following treatment with various active components, as discussed in Example 8.
  • FIG. 10 is a graphical illustration showing cell survival following treatment of cells with various active ingredients, as discussed in Example 10.
  • compositions and methods have been discovered that surprisingly allow for reducing the signs of skin aging.
  • the methods of the present disclosure have a broad and significant impact, as they increase adipocyte size and number (“adipogenesis”) and lipid production (“lipogenesis”) to result in a more youthful appearance of aged skin of the face and body.
  • adipogenesis refers to increased proliferation of adipocytes and/or increased differentiation of adipose-derived stem cells.
  • adipocyte cell number and/or lipid production within adipocytes can reduce the signs of skin aging, including counteracting skin thinning, increasing overall fullness, increasing skin firmness and increasing skin resiliency.
  • body refers to an individual's entire body, and particularly, includes the regions of the face (including forehead, cheeks, chin, and eyelids), neck, shoulders, breast, chest, legs, hands, feet and vulvar area including vulvar skin, for example, the vulva, labia, labia majora, labia minor, mons pubis, vulval vestibule, and combinations thereof.
  • compositions can be topically applied, alone or in combination, to an individual's skin as active ingredients in compositions to reduce the signs of skin aging.
  • active ingredients of the compositions have been previously known to stimulate collagen and elastin, it has now been unexpectedly found that these active ingredients increase adipogenesis and/or lipogenesis, thereby increasing the number and size of adipocytes in subcutaneous adipose tissue found directly below the skin. This provides the user with plumper, fuller skin and a more youthful, smoother skin appearance.
  • compositions for reducing the signs of skin aging of the face and body generally include an Undaria extract as the active ingredient.
  • extract refers to the active solid components from the Undaria plant.
  • An Undaria extract is an extract obtained from Undaria, a genus of brown alga that includes U. crenata, U. peterseniana, U. pinnatifida and U. undarioides. As stated above, Undaria extracts are known to stimulate collagen and elastin, and have specifically been described in vendor literature to increase 14 genes linked to collagen and elastin production.
  • Undaria spp. are brown algae plants that contain fucoidan in the cells walls.
  • Undaria extract refers to a liquid extract from the Undaria plant, however, does not include an extract that has been further supplemented/standardized for fucoidan content.
  • the Undaria extracts for use in the topical compositions of the present disclosure include extracts obtained by soaking or passing the Undaria algae plants in/over water with no further chemical treatment. The soaking/passing over can be accomplished with any method known in the extraction arts, such as, for example, lixiviation, infusion steeping, percolation, extraction, and the like, and combinations thereof.
  • the Undaria plant could be mascerated to further obtain the extract. Additionally, the water used in these processes could be heated to obtain the Undaria extract.
  • lixiviation refers to a technique where water is slowly passed over a solid (here, Undaria) in a layer of varying depth to extract soluble material.
  • the general technique is described in FR 2693917, which is incorporated herein to the extent it is consistent herewith, and is performed at room temperature.
  • the extract is further diluted with diluents including water, glycerin, propanediol, butylene glycol, propylene glycol and combinations thereof.
  • Undaria extracts that are supplemented/standardized for fucoidan content typically are obtained by an extraction procedure utilizing an acid/water mixture having a pH of between 0 and 2, preferably between about 0 and 1, at temperatures between about 0 and 30°C, preferably between about 15 and 25°C.
  • Fucoidan has been shown in literature to inhibit adipogenesis (Kim, K.J. et al, "Fucoidan from the sporophyll of Undaria pinnatifida suppresses adipocyte differentiation by inhibition of inflammation-related cytokines in 3T3-L1 cells," Nutr. Res. 32(6): 439-447). Further, as shown in the Examples below, MARITECH® REVERSE (Cambridge, Australia), which is standardized to at least 85% fucoidan, did not increase adipogenesis and lipogenesis. As disclosed herein, however, the Undaria extracts used in the compositions of the present disclosure, which are of the same species known to contain fucoidan, surprisingly and unexpectedly resulted in an increase in adipogenesis and lipogenesis.
  • Suitable Undaria extracts can be obtained from commercially available sources (e.g., Barnet Products Corp., Englewood Cliffs, NJ; Changsha Organic Herb Inc., Hunan, China).
  • a particularly suitable commercially available formulation including Undaria extract can be, for example, UNDARINETM, which is a formulation including glycerin, water and U pinnatifida extract (commercially available from Barnet Products Corp., Englewood Cliffs, NJ).
  • Undaria extract can be, for example, the U pinnatifida extract WAKAMINE® (INCI: water (and) Undaria pinnatifida extract), commercially available from SOLIANCE (France), which has previously been used to lighten skin and prevent age-spots.
  • WAKAMINE® U pinnatifida extract
  • SOLIANCE SOLIANCE
  • Suitable amounts of an Undaria extract for use in the topical compositions can be from about 0.01% (w/w) to about 10%> (w/w), from about 0.05%> (w/w) to about 7.5%) (w/w), from about 0.1 %> (w/w) to about 5%> (w/w), and from about 1 %> (w/w) to about 5 %> (w/w).
  • w/w refers to the amount of the component "by weight of the composition”.
  • the present disclosure is directed to a composition including a Bidens extract as the active ingredient.
  • a Bidens extract refers to the active solid components from the Bidens plant.
  • Bidens is a genus of plants in the Asteraceae family that includes many species members. Bidens is known to increase collagen and elastin production. Surprisingly and unexpectedly, as disclosed herein, Bidens extract has been found to increase adipogenesis and lipogenesis.
  • Suitable Bidens extracts include extracts of Bidens alba, Bidens amplectens, Bidens amplissima, Bidens aristosa, Bidens asymmetrica, Bidens aurea, Bidens beckii, Bidens bidentoides, Bidens bigelovii, Bidens bipinnata, Bidens biternata, Bidens campy lotheca, Bidens cernua, Bidens cervicata, Bidens chippii, Bidens conjuncta, Bidens connata, Bidens coronata, Bidens cosmoides, Bidens cynapiifolia, Bidens discoidea, Bidens eatonii, Bidens ferulifolia, Bidens forbesii, Bidens frondosa, Bidens gardneri, Bidens hawaiensis, Bidens henryi, Bidens hen
  • Bidens extracts can be, for example, Bidens pilosa extract, Bidens bipinnata extract, and Bidens tripartita extract.
  • Suitable Bidens extract can be obtained from commercially available sources (e.g., Chemyunion Quimica Ltd., Sao Paulo, Brazil; and Carrubba Inc., Milford, CT).
  • Suitable Bidens extracts can also include Bidens extract blends with hydrophilic carriers such as for example, water, glycerin, propanediol, butylene glycol, propylene glycol and combinations thereof and Bidens extract blends with hydrophobic carriers such as for example natural oils, synthetic oils and combinations thereof.
  • a particularly suitable Bidens extract can be, for example, ECOBIDENSTM (commercially available from Chemyunion Quimica Ltd., Sao Paulo, Brazil).
  • ECOBIDENSTM is a glycerin extract of Bidens pilosa L.
  • Other commercially available Bidens extracts include, for example, Water Agrimony Extract H.G., a B. tripartita extract from Provital Group (Spain); Bidens Extract M9983-WS, a B. pilosa extract, and Bidens bipinnata Extract N0061-WS, a B. bipinnata extract, both available from Carrubba Inc. (Milford, Connecticut).
  • Suitable amounts of Bidens extract in the topical compositions can be from about 0.01% (w/w) to about 10% (w/w), from about 0.05% (w/w) to about 7.5% (w/w), from about 0.1 % (w/w) to about 5% (w/w), and from about 1% (w/w) to about 5 % (w/w).
  • the present disclosure is directed to a composition including a combination of the active ingredients of an Undaria extract and a Bidens extract.
  • suitable amounts of the Undaria extract in the topical compositions can be from about 0.01% (w/w) to about 20% (w/w), from about 0.05% (w/w) to about 15% (w/w), and from about 0.1% (w/w) to about 10% (w/w).
  • Suitable amounts of Bidens extract in the topical compositions can be from about 0.01% (w/w) to about 20%) (w/w), from about 0.05% (w/w) to about 15% (w/w), from about 0.1% (w/w) to about 10%) (w/w), from about 0.1% (w/w) to about 5% (w/w), and from about 1% (w/w) to about 5% (w/w).
  • compositions described herein can further include additional ingredients and optional ingredients.
  • compositions include a carrier with the active ingredient(s).
  • the composition when the topical composition is to be applied to the vulvar region of an individual, the composition includes the active ingredient(s) and a hydrophilic carrier, a hydrophilic thickener, and/or a penetration enhancer.
  • Suitable hydrophilic carriers can be, for example, water, alcohols, glycerin, glycerin derivatives, glycols, water-soluble emollients, and combinations thereof.
  • Suitable examples of alcohols could include, but are not to be limited to, ethanol and isopropyl alcohol.
  • Suitable examples of glycerin derivatives could include, but are not to be limited to, PEG-7 glyceryl cocoate.
  • Suitable glycols could include, but are not to be limited to, propylene glycol, butylene glycol, pentylene glycol, ethoxydiglycol, dipropylene glycol, propanediol, and PEG-8.
  • Suitable examples of water-soluble emollients could include, but are not to be limited to, PEG-6 Caprylic Capric Glycerides, Hydrolyzed Jojoba Esters, and PEG- 10 Sunflower Glycerides.
  • the topical compositions are liquid compositions desirably containing water as the carrier.
  • Suitable amounts of water can be from about 0.1% by weight of the composition to about 99.9% by weight of the composition. More typically, the amount of water can be from about 40% by weight of the composition to about 99.9% by weight of the composition. Preferably, the amount of water can be from about 60% by weight of the composition to about 99.9% by weight of the composition.
  • the composition includes the active ingredient(s) and a hydrophobic carrier.
  • Suitable hydrophobic carriers can be, for example, natural oils, synthetic oils and combinations thereof.
  • the topical compositions described herein can further include a skin penetrating enhancer or a mixture of skin penetration enhancers.
  • a skin penetrating enhancer allows for the composition to pass through the epidermal layer and the dermal layer of the skin to reach the adipose tissue that underlies the skin wherein adipocytes are increased in number and/or size. This may be accomplished by a number of different mechanisms including, for example, by extracting lipids from the stratum corneum, increasing the partitioning of the Undaria and Bidens into the skin, and disrupting the lipid bilayer of the stratum corneum, thus rendering the stratum corneum structure more fluid and increasing the ability of the Undaria and Bidens to diffuse through the stratum corneum.
  • suitable skin penetration enhancers include sulfoxides, alcohols, fatty acids, fatty acid esters, polyols, amides, surfactants, terpenes, alkanones, and organic acids, among others.
  • suitable sulfoxides include dimethylsulfoxide (DMSO) and decylmethylsulfoxide, among others.
  • Suitable alcohols include alkanols such as ethanol, propanol, butanol, pentanol, hexanol, octanol, n-octanol, nonanol, decanol, 2-butanol, 2-pentanol, and benzyl alcohol; fatty alcohols, such as caprylic alcohol, decyl alcohol, lauryl alcohol, 2-lauryl alcohol, myristyl alcohol, cetyl alcohol, stearyl alcohol, oleyl alcohol, linoleyl alcohol, and linolenyl alcohol; and isopropyl alcohol.
  • alkanols such as ethanol, propanol, butanol, pentanol, hexanol, octanol, n-octanol, nonanol, decanol, 2-butanol, 2-pentanol, and benzyl alcohol
  • fatty alcohols
  • Suitable fatty acids include linear fatty acids such as valeric acid, heptanoic acid, pelagonic acid, caproic acid, capric acid, lauric acid, myristic acid, stearic acid, oleic acid, and caprylic acid; and branched fatty acids, such as isovaleric acid, neopentanoic acid, neoheptanoic acid, neononanoic acid, trimethyl hexanoic acid, neodecanoic acid, and isostearic acid.
  • linear fatty acids such as valeric acid, heptanoic acid, pelagonic acid, caproic acid, capric acid, lauric acid, myristic acid, stearic acid, oleic acid, and caprylic acid
  • branched fatty acids such as isovaleric acid, neopentanoic acid, neoheptanoic acid, neononanoic acid, trimethyl hexanoic acid
  • Suitable fatty acid esters include aliphatic fatty acid esters such as isopropyl n-butyrate, isopropyl n-hexanoate, isopropyl n- decanoate, isopropyl myristate, isopropyl palmitate, and octyldodecyl myristate; alkyl fatty acid esters such as ethyl acetate, butyl acetate, methyl acetate, methylvalerate, methylpropionate, diethyl sebacate, and ethyl oleate; and diisopropyl adipate and dimethyl isosorbide.
  • aliphatic fatty acid esters such as isopropyl n-butyrate, isopropyl n-hexanoate, isopropyl n- decanoate, isopropyl myristate, isopropyl palmitate, and octyld
  • suitable polyols include propylene glycol, butylene glycol, polyethylene glycol, ethylene glycol, diethylene glycol, triethylene glycol, dipropylene glycol, ethoxydiglycol, pentylene glycol, glycerol, propanediol, butanediol, pentanediol, hexanetriol, and glycerin.
  • Suitable amides include urea, dimethylacetamide, diethyltoluamide, dimethylformamide (DMF), dimethyloctamide, dimethyldecamide, biodegradable cyclic urea (e.g., l-alkyl-4-imidazoline-2-one), pyrrolidone derivatives, biodegradable pyrrolidone derivatives (e.g., fatty acid esters of N-(2-hydroxyethyl)-2- pyrrolidone), cyclic amides, hexamethylenelauramide and its derivatives, diethanolamine, and triethanolamine.
  • urea dimethylacetamide, diethyltoluamide, dimethylformamide (DMF), dimethyloctamide, dimethyldecamide, biodegradable cyclic urea (e.g., l-alkyl-4-imidazoline-2-one), pyrrolidone derivatives, biodegradable pyrrolidone derivatives (
  • pyrrolidone derivatives include l-methyl-2 -pyrrolidone, 2-pyrrolidone, 1 -lauryl-2 -pyrrolidone, l-methyl-4-carboxy-2-pyrrolidone, l-hexyl-4- carboxy-2-pyrrolidone, 1 -lauryl-4-carboxy-2-pyrrolidone, 1 -methyl-4-methoxycarbonyl-2- pyrrolidone, 1 -hexyl-4-methoxycarbonyl-2 -pyrrolidone, 1 -lauryl-4-methoxycarbonyl-2- pyrrolidone, N-cyclohexylpyrrolidone, N-dimethylaminopropylpyrrolidone, N- cocoalkypyrrolidone, N-tallowalkylpyrrolidone, and N-methylpyrrolidone.
  • cyclic amides examples include l-dodecylazacycloheptane-2-one (e.g., Azone®), 1- geranylazacycloheptan-2-one, l-farnesylazacycloheptan-2-one, 1- geranylgeranylazacycloheptan-2-one, 1 -(3 ,7-dimethyloctyl)azacycloheptan-2-one, 1 - (3,7,1 l-trimethyldodecyl)azacyclohaptane-2-one, l-geranylazacyclohexane-2-one, 1- geranylazacyclopentan-2,5-dione, and 1 -farnesylazacyclopentan-2-one.
  • Azone® 1- geranylazacycloheptan-2-one
  • l-farnesylazacycloheptan-2-one 1- geranylazacycloheptan-2-one
  • the compositions of the present disclosure include from about 0.01% (by weight of the composition) to about 25% (by weight of the composition) of a skin penetration enhancer, including from about 1% (by weight of the composition) to about 15% (by weight of the composition) of a skin penetration enhancer, and including from about 2% (by weight of the composition) to about 10% (by weight of the composition) of a skin penetration enhancer.
  • the Undaria and/or Bidens-contdin g topical compositions may be formulated with a polar co-solvent to further increase the permeability of the Undaria and Bidens into the skin.
  • the polar co-solvent is fully miscible in the composition, and has a high affinity for the intercellular spaces in the stratum corneum.
  • polar co-solvents with such characteristics are driven by osmosis into the intercellular spaces in the stratum corneum, causing the stratum corneum to swell. In such a swollen state, the intercellular spaces are more liquid-like and disordered, which enables the Undaria and/or Bidens extracts to more easily diffuse through the stratum corneum.
  • Suitable polar co-solvents for inclusion in the compositions of the present disclosure include glycerin, propanediol, ethanol, propylene glycol, butanol, isopropanol, propanol, dimethyl isosorbide, butylene glycol, polyethylene glycol, dipropylene glycol, ethoxydiglycol, pentylene glycol, and combinations thereof.
  • the compositions of the present disclosure include from about 1%) (by weight of the composition) to about 99% (by weight of the composition) of a polar co-solvent, including from about 1% (by weight of the composition) to about 75% (by weight of the composition) of a polar co-solvent, including from about 1% (by weight of the composition) to about 50% (by weight of the composition) of a polar co-solvent, including from about 1.5% (by weight of the composition) to about 25% (by weight of the composition) of a polar co-solvent, including from about 2% (by weight of the composition) to about 15% (by weight of the composition) of a polar co-solvent, and including from about 2.5% (by weight of the composition) to about 10%> (by weight of the composition) of a polar co-solvent.
  • compositions can further include beta- sitosterol. It is believed that in combination with Undaria and/or Bidens extract, beta- sitosterol further reduces signs of skin aging of the face and body by stimulating adipogenesis and lipogenesis, and further stimulating collagen, elastin and extracellular matrix production.
  • Suitable amounts of beta-sitosterol can be from about 0.001%> by weight of the composition to about 10.0% by weight of the composition. More typically, the amount of beta-sitosterol can be from about 0.005%) by weight of the composition to about 7.5% by weight of the composition. Even more suitable, the amount of beta-sitosterol can be from about 0.01%) by weight of the composition to about 5.0%> by weight of the composition.
  • the composition can further include other known collagen, elastin, and extracellular matrix-stimulating ingredients.
  • Collagen is a protein found in the connective tissue of the skin and other tissues of the body.
  • Suitable collagen enhancers can be, for example, vitamins such as ascorbic acid and derivatives thereof, peptides such as palmitoyl tripeptide-5, botanical extracts such as pomegranate or mushroom, and minerals such as hematite.
  • Elastin is a protein found in the connective tissue of the skin and other tissues of the body.
  • Suitable elastin enhancers can be, for example, vitamins such as ascorbic acid and derivatives thereof, peptides such palmitoyl hexapeptide-12, botanical extracts such as kudzu, horsetail, rice, dill and rosemary, and minerals such as zinc and copper.
  • the compositions can further include a vasodilator.
  • Vasodilators can increase the blood flow within the skin. Suitable vasodilators can be, for example, glyceryl trinitrate, resveratrol, caffeine, ginger extract, ginseng and other botanical extracts such as, for example, hawthorn, mint, ivy, coffee and tea.
  • the compositions can further include a skin soothing agent.
  • skin soothing agent refers to compounds that reduce or prevent skin irritation. Skin irritation can result from loss of moisture, a change in pH, sweat, contact dermatitis from perfumes, powders, laundry detergent from clothing, and other compounds.
  • Skin soothing agents can reduce irritation by neutralizing an irritant, down-regulating inflammatory cascades in the skin, and/or providing a protective layer on the skin.
  • Suitable skin soothing agents can be, for example, botanical extracts such as calendula, chamomile, aloe, comfrey, coneflower; active materials such as allantoin, bisabolol, panthenol, beta- glucan, colloidal oatmeal, and ingredient blends such as SYMCALMIN (INCI: butylene glycol, pentylene glycol, hydroxyphenyl propamidobenzoic acid; commercially available from Symrise (Holzmiden, Germany) and SEPICALM (INCI: sodium palmitoyl proline, nymphaea alba flower extract; commercially available from Seppic (Fairfield, NJ).
  • botanical extracts such as calendula, chamomile, aloe, comfrey, coneflower
  • active materials such as allantoin, bisabol
  • compositions can further include a humectant.
  • Humectants can elevate the hydration of the skin, in particular the epidermis and the dermis.
  • Suitable humectants can be, for example, glycerol, glycerin, lactic acid, urea, aloe vera, betaine, hyaluronic acid, propanediol, propylene glycol, butylene glycol, and combinations thereof.
  • compositions can further include an emulsifier, and in particular, an emulsifier that creates liquid crystalline networks or liposomal networks.
  • emulsifiers include, for example, OLIVEM® 1000 (INCI: Cetearyl Olivate (and) Sorbitan Olivate; commercially available from HallStar Company (Chicago, IL)), ArlacelTM LC (INCI: Sorbitan Stearate (and) Sorbityl Laurate; commercially available from Croda (Edison, NJ), CRYSTALCAST® MM (INCI: Beta Sitosterol (and) Sucrose Stearate (and) Sucrose Distearate (and) Cetyl Alcohol (and) Stearyl Alcohol; commercially available from MMP Inc.
  • Suitable emulsifiers include lecithin, hydrogenated lecithin, lysolecithin, phosphatidylcholine, phospholipids, and combinations thereof.
  • compositions can further include a preservative to preserve the stability.
  • Preservatives can also prevent the growth of microbial organisms in the compositions.
  • Suitable preservatives are known in the art, and include, for example, methylparaben, phenoxyethanol, capryl glycol, glyceryl caprylate, benzoic acid, sorbic acid, gallic acid, propylparaben and combinations thereof.
  • compositions can further include a pH adjuster to control/maintain the pH of the composition within the range of skin pH.
  • a suitable pH range of the composition can be from about 3.5 to about 6.
  • compositions can further include fragrances, scents, dyes, surfactants, rheology modifiers, film formers and other components known to be useful in personal care formulations.
  • the present disclosure is directed to methods of using the topical compositions to reduce skin aging of an individual's face and body.
  • the present disclosure is directed to a method for reducing signs of skin aging of the face and body in an individual in need thereof.
  • skin aging refers to increased skin wrinkling, increased appearance of fine lines, thinning skin, sagging skin, skin dryness, and skin itchiness.
  • the method includes topically applying a composition including an Undaria extract to a target skin region of the individual.
  • the target skin region can be, for example, facial skin, neck skin, breast skin, shoulder skin, chest skin, leg skin, hand skin, feet skin, and combinations thereof.
  • the present disclosure is directed to a method for reducing signs of vulvar skin aging in an individual in need thereof.
  • vulvar skin aging refers to skin wrinkling, increased appearance of fine lines, thinning skin, sagging skin, skin dryness, and skin itchiness of the skin in the vulvar region, including the vulva, labia, labia majora, labia minor, mons pubis, vulval vestibule, and combinations thereof.
  • the method includes topically applying a composition including an Undaria extract to a target skin region of the individual.
  • the target skin region can also be, for example, vulvar skin, for example, the vulva, labia, labia majora, labia minor, mons pubis, vulval vestibule, and combinations thereof.
  • the present disclosure is directed to a method for increasing adipogenesis in an individual in need thereof.
  • the method includes topically applying a composition including an Undaria extract to a target skin region of the individual.
  • the target skin region can be, for example, facial skin, neck skin, breast skin, shoulder skin, chest skin, leg skin, hand skin, feet skin, and combinations thereof.
  • the target skin region can also be, for example, vulvar skin, for example, the vulva, labia, labia majora, labia minor, mons pubis, vulval vestibule, and combinations thereof.
  • the present disclosure is directed to a method for increasing lipogenesis in an individual in need thereof.
  • the method includes topically applying a composition including an Undaria extract to a target skin region of the individual.
  • the target skin region can be, for example, facial skin, neck skin, breast skin, shoulder skin, chest skin, leg skin, hand skin, feet skin, and combinations thereof.
  • the target skin region can also be, for example, vulvar skin, for example, the vulva, labia, labia majora, labia minor, mons pubis, vulval vestibule and combinations thereof.
  • the present disclosure is directed to a method for treating vaginal vulvar atrophy in an individual in need thereof.
  • vulvar atrophy refers to the thinning, drying and inflammation of the tissue in and around the vulvar region. Typically, vulvar atrophy occurs after menopause, but can also develop during breast-feeding or at any other time an individual's estrogen production declines.
  • the method comprises topically applying a composition that comprises a Undaria extract and a hydrophilic carrier to a vulvar skin region of the individual.
  • the present disclosure is directed to a method for reducing signs of skin aging of the face and body in an individual in need thereof.
  • the method includes topically applying a composition including a Bidens extract to a target skin region of the individual.
  • the target skin region can be, for example, facial skin, neck skin, breast skin, shoulder skin, chest skin, leg skin, hand skin, feet skin, and combinations thereof.
  • the present disclosure is directed to a method for reducing signs of vulvar skin aging in an individual in need thereof.
  • the method includes topically applying a composition including a Bidens extract to a target skin region of the individual.
  • the target skin region can be, for example, vulvar skin, for example, the vulva, labia, labia majora, labia minor, mons pubis, vulval vestibule and combinations thereof.
  • the present disclosure is directed to a method for increasing adipogenesis in an individual in need thereof.
  • the method includes topically applying a composition including a Bidens extract to a target skin region of the individual.
  • the target skin region can be, for example, facial skin, neck skin, breast skin, shoulder skin, chest skin, leg skin, hand skin, feet skin, and combinations thereof.
  • the target skin region can also be, for example, vulvar skin, for example, the vulva, labia, labia majora, labia minor, mons pubis, vulval vestibule and combinations thereof.
  • the present disclosure is directed to a method for increasing lipogenesis in an individual in need thereof.
  • the method includes topically applying a composition including a Bidens extract to a target skin region of the individual.
  • the target skin region can be, for example, facial skin, neck skin, breast skin, shoulder skin, chest skin, leg skin, hand skin, feet skin, and combinations thereof.
  • the target skin region can also be, for example, vulvar skin, for example, the vulva, labia, labia majora, labia minor, mons pubis, vulval vestibule and combinations thereof.
  • the present disclosure is directed to a method for treating vulvar atrophy in an individual in need thereof.
  • the method comprises topically applying a composition that comprises a Bidens extract and a hydrophilic carrier to a vulvar skin region of the individual.
  • the present disclosure is directed to a method for reducing signs of skin aging of the face and body in an individual in need thereof.
  • the method includes topically applying a composition including an Undaria extract and a Bidens extract to a target skin region of the individual.
  • the target skin region can be, for example, facial skin, neck skin, breast skin, shoulder skin, chest skin, leg skin, hand skin, feet skin, and combinations thereof.
  • the present disclosure is directed to a method for reducing signs of vulvar skin aging in an individual in need thereof.
  • the method includes topically applying a composition including an Undaria extract and a Bidens extract to a target skin region of the individual.
  • the target skin region can be, for example, vulvar skin, for example, the vulva, labia, labia majora, labia minor, mons pubis, vulval vestibule and combinations thereof.
  • the present disclosure is directed to a method for increasing adipogenesis in an individual in need thereof.
  • the method includes topically applying a composition including an Undaria extract and a Bidens extract to a target skin region of the individual.
  • the target skin region can be, for example, facial skin, neck skin, breast skin, shoulder skin, chest skin, leg skin, hand skin, feet skin, and combinations thereof.
  • the target skin region can also be, for example, vulvar skin, for example, the vulva, labia, labia majora, labia minor, mons pubis, vulval vestibule and combinations thereof.
  • the present disclosure is directed to a method for increasing lipogenesis in an individual in need thereof.
  • the method includes topically applying a composition including an Undaria extract and a Bidens extract to a target skin region of the individual.
  • the target skin region can be, for example, facial skin, neck skin, breast skin, shoulder skin, chest skin, leg skin, hand skin, feet skin, and combinations thereof.
  • the target skin region can also be, for example, vulvar skin, for example, the vulva, labia, labia majora, labia minor, mons pubis, vulval vestibule and combinations thereof.
  • an "individual in need” refers to an individual having skin showing visible signs of aging such as, for example, wrinkles, fine lines, thinning skin, sagging skin, skin dryness, skin itchiness, skin fragility, loss of skin elasticity, and combinations thereof.
  • the methods disclosed herein are directed to a subset of the general population such that, in these embodiments, not all of the general population may benefit from the methods.
  • the term "individual” refers to a male human or a female human. In certain embodiments, the individual is a postmenopausal female human.
  • the topical compositions used in the methods described herein can further include additional ingredients as described herein and other components known to be useful in personal care formulations.
  • the topical compositions can be applied to the target skin region by any suitable delivery vehicle.
  • the composition can be applied as a lotion, as a wash, as a gel, as a salve, as an ointment, as a cream, as a solid stick and as a foam.
  • the composition can be applied with a wipe, with mitts and gloves, using an aerosol dispenser, using a pump spray, using a trigger spray and using a squeeze bottle.
  • compositions can be applied daily, every other day, every couple of days, every week, every month, and every year, as desired.
  • the compositions can be applied multiple times per day, multiple times per week and/or multiple times per month.
  • the compositions of the present disclosure can be used with additional skin care compositions as part of a skin care regimen.
  • a skin care regimen For example, in facial treatment and care, users typically use multiple products for cleansing, toning, and treating the skin of the face.
  • the first product comprises a first composition typically capable of providing a first benefit to a user
  • the second product comprises a second composition typically capable of providing a second benefit to a user.
  • at least one of the products of the regime includes the topical composition of the present disclosure, thereby providing the benefit of reducing signs of skin aging.
  • first product and second product can independently provide any benefit known in the art of the particular care regimen, in each particular multi-product care regimen, the first product and second product may include different compositions and thus, provide different benefits to the user.
  • the multi-product care regimen can include more than two products and can be configured such to provide a multiple day regimen.
  • the multi-product care regimen provides skin care for multiple days and, as such, a first product includes, for example, a cleansing composition, a second product includes the anti-skin aging composition of the present disclosure, a third product includes the same cleansing composition as the first product, and a fourth product includes the same anti-skin aging composition as the second product.
  • compositions for cleansing, toning, treating, moisturizing, protecting, finishing, and the like can include compositions for cleansing, toning, treating, moisturizing, protecting, finishing, and the like.
  • the cleansing composition may be in any form known in the art, such as, for example, hand soaps, body soaps, body washes, shampoos, surface cleaners, dish soaps, facial cleansers, hand washes, and the like.
  • these types of cleansing compositions typically include at least one foaming agent, such as a surfactant.
  • a surfactant such as a surfactant
  • the compositions may comprise a thickener, a swellable clay, a foaming agent (which may or may not comprise a surfactant (e.g., ethoxylated skin conditioning agents, solubilizers, and derivatized silicone polymers)), and optionally a solvent or other carrier.
  • a surfactant e.g., ethoxylated skin conditioning agents, solubilizers, and derivatized silicone polymers
  • solvent or other carrier e.g., a surfactant, e.g., ethoxylated skin conditioning agents, solubilizers, and derivatized silicone polymers
  • Suitable surfactants for use in the cleansing composition include anionic surfactants, amphoteric surfactants, cationic surfactants, zwitterionic surfactants, non-ionic surfactants, and combinations thereof.
  • Suitable anionic surfactants include, for example, alkyl sulfates, alkyl ether sulfates, alkyl aryl sulfonates, alpha-olefm sulfonates, alkali metal or ammonium salts of alkyl sulfates, alkali metal or ammonium salts of alkyl ether sulfates, alkyl phosphates, silicone phosphates, alkyl glyceryl sulfonates, alkyl sulfosuccinates, alkyl taurates, acyl taurates, alkyl sarcosinates, acyl sarcosinates, sulfoacetates, alkyl phosphate esters, mono alkyl succinates, monoalkyl maleates, sulphoacetates, acyl isethionates, alkyl carboxylates, phosphate esters, sulphosuccinate
  • anionic surfactants include sodium lauryl sulphate, sodium lauryl ether sulphate, ammonium lauryl sulphosuccinate, ammonium lauryl sulphate, ammonium lauryl ether sulphate, sodium dodecylbenzene sulphonate, triethanolamine dodecylbenzene sulphonate, sodium cocoyl isethionate, sodium lauroyl isethionate, sodium N-lauryl sarcosinate, and combinations thereof.
  • Suitable cationic surfactants include, for example, alkyl ammonium salts, polymeric ammonium salts, alkyl pyridinium salts, aryl ammonium salts, alkyl aryl ammonium salts, silicone quaternary ammonium compounds, and combinations thereof.
  • Specific examples of cationic surfactants include behenyltrimonium chloride, stearlkonium chloride, distearalkonium chloride, chlorohexidine diglutamate, polyhexamethylene biguanide (PHMB), cetyl pyridinium chloride, benzammonium chloride, benzalkonium chloride, and combinations thereof.
  • Suitable amphoteric surfactants include, for example, betaines, alkylamido betaines, sulfobetaines, N-alkyl betaines, sultaines, amphoacetates, amophodiacetates, imidazoline carboxylates, sarcosinates, acylamphoglycinates, such as cocamphocarboxyglycinates and acylamphopropionates, and combinations thereof.
  • amphoteric surfactants include cocamidopropyl betaine, lauramidopropyl betaine, meadowfoamamidopropyl betaine, sodium cocoyl sarcosinate, sodium cocamphoacetate, disodium cocoamphodiacetate, ammonium cocoyl sarcosinate, sodium cocoamphopropionate, and combinations thereof.
  • Suitable zwitterionic surfactants include, for example, alkyl amine oxides, silicone amine oxides, and combinations thereof.
  • Specific examples of suitable zwitterionic surfactants include, for example, 4- [N,N-di(2 -hydroxy ethyl)-N- octadecylammonio]-butane- 1 -carboxylate, S-[S-3-hydroxypropyl-S-hexadecylsulfonio]-3- hydroxypentane-1 -sulfate, 3-[P,P-diethyl-P-3,6,9-trioxatetradexopcylphosphonio]-2- hydroxypropane-1 -phosphate, 3-[N,N-dipropyl-N-3-dodecoxy-2-hydroxypropylammonio]- propane- 1 -phosphonate, 3 -(N,N-dimethyl-N-hexadecylammonio]
  • Suitable non-ionic surfactants include, for example, mono- and di- alkanolamides such as, for example, cocamide MEA and cocamide DEA, amine oxides, alkyl polyglucosides, ethoxylated silicones, ethoxylated alcohols, ethoxylated carboxylic acids, ethoxylated amines, ethoxylated amides, ethoxylated alkylolamides, ethoxylated alkylphenols, ethoxylated glyceryl esters, ethoxylated sorbitan esters, ethoxylated phosphate esters, glycol stearate, glyceryl stearate, and combinations thereof. It will be recognized by one skilled in the art that many of the nonionic surfactants described herein may act to improve the foaming properties of the cleansing composition of the multi- product care system, and may provide a more compact, reduced bubble size or creamy foam.
  • the cleansing composition may also include a thickener, which acts to thicken or increase the viscosity of the cleansing formulation.
  • a thickener which acts to thicken or increase the viscosity of the cleansing formulation.
  • a variety of thickeners may be used in the cleansing compositions described herein.
  • the thickener may be a cellulosic thickener or gum.
  • Suitable cellulosic or gum thickeners include xanthan gum, agar, alginates, carrageenan, furcellaran, guar, cationic guar, gum arabic, gum tragacanth, karaya gum, locust bean gum, dextran, starch, modified starches, gellan gum, carboxymethylcellulose, hydroxypropylcellulose, hydroyethylcellulose, propylene glycol alginate, hydroxypropyl guar, amylopectin, cellulose gum, chitosan, modified chitosan, hydroxypropyl methylcellulose, microcrystalline cellulose, silica, fumed silica, colloidal silica, dehydroxanthan gum, non-acrylic based carbomers, and combinations thereof.
  • the thickener may be an acrylic based polymer.
  • suitable acrylic based polymer thickeners include acrylates/C IOCS 0 alkyl acrylate crosspolymers, certain carbomers, acrylates copolymers, aminoacrylates copolymers, and combinations thereof.
  • acrylic based polymer thickeners examples include Structure® Plus (Akzo Nobel, Pasadena, CA), which is an acrylates/aminoacrylates/C 10-30 alkyl PEG-20 itaconate copolymer, Carbopol® Aqua SF- 1 Polymer (Lubrizol Advanced Materials, Cleveland, OH), which is an acrylates copolymer, PEMULEN® TR-1 and TR-2 and Carbopol® ETD 2020 (available from Lubrizol Advanced Materials), which are acrylates/C 10-30 alkyl acrylates crosspolymers, and the Carbopol® Ultrez series of polymers (available from Lubrizol Advanced Materials), which are carbomers.
  • Additional suitable agents for use in the cleansing composition may include humectants, preservatives, fragrances, chelating agents, and combinations thereof.
  • a skin care regime may further include a toning composition.
  • Toning compositions provide such benefits as closing pores of a user's skin, restoring the natural pH of the skin (typically, a pH of from about 5.0 to about 5.5), removing skin impurities (e.g., dirt, oils, sebum, make-up, pollutants, and the like), hydrating the skin, and generally preparing the skin for treatment using a treatment composition, such as the anti-aging composition of the present disclosure, and/or an additional treatment composition as described below.
  • a treatment composition such as the anti-aging composition of the present disclosure, and/or an additional treatment composition as described below.
  • toning compositions for skin care include astringents, humectants, carriers, and combinations thereof.
  • Suitable astringents include, for example, ethanol, witch hazel, rose water, alum, oatmeal, yarrow, bayberry, cold water, rubbing alcohol, astringent preparations such as silver nitrate, zinc oxide, zinc sulfate, Burow's solution, tincture of benzoin, and vegetable substances such as tannic and gallic acid, and combinations thereof.
  • cold water refers to water having a temperature below room temperature (approximately 25°C (77°F)).
  • Suitable humectants include, for example, glycerin, glycerin derivatives, sodium hyaluronate, betaine, amino acids, glycosaminoglycans, honey, sorbitol, glycols, polyols, sugars, hydrogenated starch hydrolysates, salts of PCA, lactic acid, lactates, and urea.
  • a particularly preferred humectant is glycerin.
  • Carriers for the toning compositions can be any carrier material typically known in the cosmetic and medical arts as a basis for ointments, lotions, creams, salves, aerosols, gels, suspensions, sprays, foams, and the like, and may be used in their art- established levels.
  • the carrier is an aqueous carrier.
  • the carrier is an alcohol carrier.
  • the alcohol carrier can be any suitable alcohol.
  • One particularly preferred alcohol is ethanol.
  • suitable carriers can also be used in the toning compositions.
  • the carriers themselves can provide the skin care benefit.
  • suitable carriers include emollients, sterols or sterol derivatives, natural and synthetic fats or oils, polyols, surfactants, esters, silicones, and other pharmaceutically acceptable carrier materials.
  • the skin care regimen includes a treatment composition for treating the skin in addition to the anti-aging composition of the present disclosure.
  • exemplary actives for the additional treatment composition may include actives that are known to have a treating effect on the skin such as improving the evenness of skin tone and reduction of acne.
  • the treatment agent can be selected from the group consisting of appearance modifying agents (e.g., exfoliating agents, skin- firming agents, anti-callous agents, anti-acne agents, wound care agents, enzyme agents, scar repair agents, humectant agents), therapeutic agents, pharmaceuticals (e.g., drugs, antioxidants, transdermal drug delivery agents, botanical extracts, vitamins, magnets, magnetic metals, and foods), xenobiotics, skin coloration agents (e.g., tanning agents, lightening agents, and brightening agents, shine control agents and drugs), shine control agents, colorant agents, surface conditioning agents (e.g., pH adjusting agents, moisturizers, skin conditioners, exfoliation agents, shaving lubricants, anti-callous agents, anti-acne agents, anti-aging agents, wound care agents, skin lipids, enzymes, scar care agents, humectants, powders, botanical extracts, and drugs) external analgesic agents, anti-inflammatory (e.g., anti-inflammatory
  • the skin care regimen includes a finishing composition.
  • a finishing composition comprises a finishing agent that typically delivers moisturization, skin protection, or a moisture-barrier for sealing in moisture to the user.
  • the finishing agent can be any moisturizing agent, skin protectant, and/or moisture-barrier enhancing agent known in the art.
  • finishing agent may be capable of providing aesthetic benefits such as skin smoothing or a powdery feel.
  • additional suitable finishing agents include skin conditioning agents (e.g., pH adjusting agents, moisturizers, skin conditioners, exfoliation agents, shaving lubricants, skin-firming agents, anti-callous agents, anti-acne agents, anti-aging agents, anti-wrinkle agents, anti-dandruff agents, wound care agents, skin lipids, enzymes, scar care agents, humectants, powders, botanical extracts, and drugs), fragrances, botanical extracts, powders, and combinations thereof.
  • skin conditioning agents e.g., pH adjusting agents, moisturizers, skin conditioners, exfoliation agents, shaving lubricants, skin-firming agents, anti-callous agents, anti-acne agents, anti-aging agents, anti-wrinkle agents, anti-dandruff agents, wound care agents, skin lipids, enzymes, scar care agents, humectants, powders, botanical extracts, and
  • compositions of the present disclosure can be used for various other daily regimens comprising steps to cleanse, treat, moisturize and protect the skin. It is understood that skin care regimens can combine all of these steps, some of these steps, or have multiple iterations of the same steps so as to provide desired benefits to the skin.
  • ADSC Human adipocyte-derived stem cells
  • 1% ADIPOFILL'INTM including propanediol, ornithine, phospholipids and glycolipids, commercially available from Lucas Meyer Cosmetics (Quebec, Canada)
  • 1% ECOBIDENSTM had a significant effect on the production of free fatty acids as compared to the negative control. More particularly, treatment of cells with ECOBIDENSTM resulted in 6.65 ⁇ / ⁇ free fatty acids production and UNDARINETM treatment resulted in 5.48 ⁇ / ⁇ free fatty acid production.
  • mouse 3T3-L1 and human adipose-derived stem cells were exposed to 1% (v/v) active ingredients for 48 hours.
  • standard growth media MesenPro RSTM medium with 200 mm of L-glutamine and 10 mg/ml of gentamycin
  • a positive control FOG.
  • ADSC cells were differentiated with STEMPRO® Adipogenesis Differentiation Kit (Invitrogen, Carlsbad, CA) for a positive control (FIG. 3B).
  • FIGS. 2C and 2D differentiated mouse 3T3-L1 cells exposed to ADIPOFILL'INTM and ECOBIDENSTM extracts stained red (as shown, became darker in color) and became more round in shape, indicating that intracellular fatty acid content increased. Similar results were obtained in human ADSC cells (see, FIGS. 3C and 3D). Minimal staining was observed in either cell line stimulated with ECOSAMBA PROTM or KOMBUCHKATM (see FIGS. 2E, 2F, 3E, and 3F). Negative controls (untreated cells) were unstained and appeared elongated in shape (see, FIG. 2A and FIG. 3A). Positive controls were also stained and became more rounded in shape (see, FIG. 2B and FIG. 3B).
  • PPAR-gamma is involved in adipogenesis signaling cascades as a known adipogenesis promoter.
  • RNA was isolated from treated ADSCs for qRT-PCR analysis. Relative expression of PPAR-gamma was compared to ⁇ -Actin (a housekeeping gene) and all samples were normalized to a negative control (untreated cells). Positive control cells were differentiated with STEMPRO® Adipogenesis Differentiation Kit (Invitrogen, Carlsbad, CA).
  • UNDARINETM Undaria extract
  • ADSC human adipose-derived stem cells
  • Undaria spp. are brown algae plants that contain fucoidan in the cell walls. Fucoidan has been shown to inhibit adipogenesis. As described in the Examples above, however, UNDARINETM surprisingly and unexpectedly promoted adipogenesis and lipid production (see, FIGS. 1 and 5).
  • mouse 3T3-1L cells were treated with an Undaria-based extract, either UNDARINETM or WAKAMINE® (an Undaria pinnatifida extract, obtained from SOLIANCE, France), or one of two standardized fucoidan Undaria extracts, MARITECH® REVERSE or MARITECH® GLYCOMIX (both obtained from Marinova Pty. Ltd.
  • a positive control included cells differentiated with STEMPRO® Adipogenesis Differentiation Kit (Invitrogen, Carlsbad, CA) and a negative control (FIG. 6E) included untreated cells. Cells were stained using Oil Red-0 staining as described above.
  • UNDARINETM and WAKAMINE® promoted adipogenesis (FIGS. 6A & 6B), whereas MARITECH® REVERSE and MARITECH® GLYCOMIX (FIGS. 6C & 6D) did not.
  • This Example confirms that fucoidans do not have an adipogenesis or lipogenesis effect on cells. And, thus, it unexpectedly demonstrates that the Undaria extracts in the compositions of the present disclosure, provide these benefits, despite being of the same genus, which is known not to promote adipogenesis.
  • mouse 3T3-1L cells were treated with the following active ingredients known to stimulate adipogenesis and/or lipogenesis: 1% (w/v) SYM3DTM (commercially available from Symrise, Teterboro, NJ), 1% (w/v) VOLUFILINETM (commercially available from Sederma, France), 1% (w/v) COMMIPHEROLINETM (commercially available from Soliance, France), 1% (w/v) BIO-BUSTYLTM (commercially available from Sederma, France), 1% (w/v) CELLACTIVE® FORM (commercially available from Rahn, USA Corp., Aurora, IL), 1% (w/v) ADIFYLINE® (commercially available from Lipotec, Spain), and 1% (w/v) VOLUFORMTM (commercially available from SEPPIC, France). More particularly, these active ingredients have been previously marketed for increasing breast size and/or plumping the neck/chest area via adipogenesis and/or lipogenesis.
  • Bidens-based extracts were tested for their effects on adipogenesis.
  • Bidens pilosa extract (ECOBIDENSTM, obtained from Chemyunion), Bidens bipinnata extract (obtained from Carrubba), Bidens pilosa extract (obtained from Carrubba), and Bidens tripartita extract (Provital Water Agrimony Extract H.G., obtained from Provital Group, Spain) were applied to mouse 3T3-1L cells at 1% (v/v). Cells were treated and grown as described above and analyzed by Oil Red O staining. A positive control (FIG.
  • mouse 3T3-1L cells stained red with Oil Red- O, demonstrating the production of fatty acids in response to the various Bidens extracts.
  • human dermal fibroblasts were stained with carboxyfluorescein succinimidyl ester (CFSE) prior to treatment with ADIPOFILL'INTM, ECOBIDENSTM, ECOSAMBA PROTM, KOMBUCHKATM, UNDARINETM or the combination of ADIPOFILL ' INTM/ECO SAMBA PROTM.
  • CFSE carboxyfluorescein succinimidyl ester
  • microarray analysis was conducted on human ADSCs to compare effects of Undaria and Bidens extracts on gene expression.
  • human ADSCs were treated with 1% (v/v) Undaria extract, UNDARINETM, or Bidens extract, ECOBIDENSTM, as described in Example 1 above for 48 hours and then allowed to differentiate in standard growth media for two weeks. After two weeks, the RNA samples were collected from the extract-treated cells and untreated control cells and submitted to a commercial service provider for microarray analysis using HEEBO human chips (Ocean Ridge Biosciences, Palm Beach Gardens, FL).
  • CYP1B1 Cytochrome P450 (lipid synthesis) up-regulated down- regulated
  • KANK4 K motif and ankyrin repeat domain up-regulated down- regulated
  • EIF2AK2 Eukaryotic Translation Initiation Factor 2- up-regulated down- Alpha Kinase regulated
  • HIF1A Hypoxia-inducible factor 1 -alpha up-regulated down- regulated
  • MMR 2 elastin microfibril interfacer 3 down- down- regulated regulated
  • TNP02 Transportin II nuclear transport receptor down- up-regulated regulated
  • CYP1B1 Cytochrome P450 (lipid synthesis) up-regulated down- regulated
  • KANK4 KN motif and ankyrin repeat domain up-regulated down- regulated
  • NRCAM Neuronal cell adhesion molecule up-regulated down- regulated
  • PPM1A protein phosphatase Mg2+/Mn2+ up-regulated down-dependent regulated
  • SPRY4 mitogen-activated protein kinase inhibitor up-regulated down- regulated
  • NDNL2 necdin-like 2 up-regulated down- regulated
  • MMRN2 elastin microfibril interfacer 3 down- down- regulated regulated
  • GBP2 guanylate binding protein 2 down- up-regulated regulated
  • HDFs human dermal fibroblasts
  • DMEM + 10% FBS growth media
  • MTT solution thiazolyl blue tetrazolium blue
  • isopropyl alcohol was added and incubated overnight at room temperature in the dark.
  • Wells were measured at OD570 and compared to untreated control cells to determine cell survival.
  • exemplary topical compositions were prepared with the following components:
  • Disodium EDTA Disodium EDTA 0.01 Sodium q.a to pH
  • topical compositions including an Undaria extract topical compositions including a Bidens extract
  • topical compositions including an Undaria extract and a Bidens extract can improve the overall fullness and appearance of aging skin by increasing adipocyte number and adipocyte lipid/free fatty acid production.
  • the compositions and methods can improve the appearance of aging skin of the face, neck and body.
  • the compositions and methods can also improve the appearance of skin of the vulva and the labia, particularly in postmenopausal women.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Birds (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne des compositions permettant de réduire le vieillissement cutané. Ces compositions peuvent être appliquées par voie topique sur une zone de peau afin de réduire ou de prévenir les rides, les ridules, l'affinement de la peau, le relâchement cutané, la sécheresse cutanée et le prurit cutané.
PCT/US2014/036223 2014-04-30 2014-04-30 Compositions topiques renfermant un extrait de bidens pour réduire les signes de l'âge WO2015167552A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/US2014/036223 WO2015167552A1 (fr) 2014-04-30 2014-04-30 Compositions topiques renfermant un extrait de bidens pour réduire les signes de l'âge

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2014/036223 WO2015167552A1 (fr) 2014-04-30 2014-04-30 Compositions topiques renfermant un extrait de bidens pour réduire les signes de l'âge

Publications (1)

Publication Number Publication Date
WO2015167552A1 true WO2015167552A1 (fr) 2015-11-05

Family

ID=54359089

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/036223 WO2015167552A1 (fr) 2014-04-30 2014-04-30 Compositions topiques renfermant un extrait de bidens pour réduire les signes de l'âge

Country Status (1)

Country Link
WO (1) WO2015167552A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160296443A1 (en) * 2015-04-08 2016-10-13 Cgtn C.V. Skin care composition having skin damage prevention and damage repairing properties
CN116421517A (zh) * 2023-04-12 2023-07-14 杭州未可品牌管理有限公司 一种皮肤抗衰老组合物及其用途和护肤品

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040028643A1 (en) * 2000-12-15 2004-02-12 Katsuyoshi Chiba Compositions for retarding skin aging
JP2004323362A (ja) * 2003-04-21 2004-11-18 Musashino Meneki Kenkyusho:Kk センダングサ属植物抽出物含有組成物
JP4073358B2 (ja) * 2003-04-28 2008-04-09 株式会社武蔵野免疫研究所 化粧品
US20110129453A1 (en) * 2009-12-02 2011-06-02 Bath & Body Works Brand Management, Inc. Topical skin composition and method for moisturizing the skin
KR20140036400A (ko) * 2012-09-13 2014-03-26 주식회사 콧데 엘라스타제 활성을 저해하는 식물성 스테롤을 유효성분으로 함유하는 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040028643A1 (en) * 2000-12-15 2004-02-12 Katsuyoshi Chiba Compositions for retarding skin aging
JP2004323362A (ja) * 2003-04-21 2004-11-18 Musashino Meneki Kenkyusho:Kk センダングサ属植物抽出物含有組成物
JP4073358B2 (ja) * 2003-04-28 2008-04-09 株式会社武蔵野免疫研究所 化粧品
US20110129453A1 (en) * 2009-12-02 2011-06-02 Bath & Body Works Brand Management, Inc. Topical skin composition and method for moisturizing the skin
KR20140036400A (ko) * 2012-09-13 2014-03-26 주식회사 콧데 엘라스타제 활성을 저해하는 식물성 스테롤을 유효성분으로 함유하는 조성물

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160296443A1 (en) * 2015-04-08 2016-10-13 Cgtn C.V. Skin care composition having skin damage prevention and damage repairing properties
CN116421517A (zh) * 2023-04-12 2023-07-14 杭州未可品牌管理有限公司 一种皮肤抗衰老组合物及其用途和护肤品
CN116421517B (zh) * 2023-04-12 2024-03-01 杭州未可品牌管理有限公司 一种皮肤抗衰老组合物及其用途和护肤品

Similar Documents

Publication Publication Date Title
AU2014392629B2 (en) Use of Undaria extract to reduce signs of skin aging
AU2014392626B2 (en) Topical compositions for stimulating adipogenesis and lipogenesis to reduce the signs of skin aging
AU2014392689B2 (en) Compositions and methods for reducing oxidative stress
AU2014392694B2 (en) Methods of reducing signs of skin aging
AU2014392692B2 (en) Use of Bidens extract to reduce signs of skin aging
AU2014392682B2 (en) Methods of reducing signs of skin aging using a combination of extracts
AU2014392686B2 (en) Topical composition including a combination of extracts for reducing signs of skin aging
WO2015167552A1 (fr) Compositions topiques renfermant un extrait de bidens pour réduire les signes de l'âge
WO2015167548A1 (fr) Compositions topiques renfermant un extrait d'undaria pour réduire les signes de l'âge

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14890877

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14890877

Country of ref document: EP

Kind code of ref document: A1